REGULATORY GUIDELINES FOR MONOCLONAL ANTIBODIES AND RELATED PRODUCTS: EMA'S STANDARDS ON DEVELOPMENT, PRODUCTION, CHARACTERIZATION & SPECIFICATIONS

The comprehensive process of monoclonal antibody development, production, characterization, and specification in the European context are engineered to precisely target various threats and have revolutionized medical approaches against diseases like cancer and infections.In Europe, European Medicines Agency (EMA) plays a prominent role in ensuring quality by establishing stringent guidelines across four distinct stages: development, production, characterization, and specification.The Development phase focuses on aligning antibody structure with its intended mechanism, biological activity, and stability.In Production, a meticulous manufacturing process description and validation are central aspects.Characterization involves a comprehensive evaluation of attributes like physicochemistry, immunochemical properties, biological activity, purity, impurities, and quantity.In the Specification stage, maintaining product consistency and compliance is paramount.Finally